Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp-EuReg) - P
5 hours ago
- #Helicobacter pylori
- #probiotics
- #clinical effectiveness
- Saccharomyces boulardii CNCM I-745 (Sb) used as an adjunct in H. pylori therapy increased effectiveness only with concomitant therapy (proton pump inhibitor plus clarithromycin-amoxicillin-metronidazole), with an odds ratio of 2.32 for success.
- Adding Sb significantly reduced overall adverse events (OR = 0.803), including lower incidences of diarrhea, nausea, dyspepsia, abdominal pain, asthenia, anorexia, heartburn, and dysgeusia.
- The study, based on real-world data from 69,922 treatment-naive cases in the Hp-EuReg registry (2013-2023), found high treatment compliance in both groups, with Sb associated with improved outcomes in European clinical practice.